Literature DB >> 2801738

Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.

B Cooper1, M Lawlor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2801738     DOI： 10.1016/s0002-9343(89)80838-1

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  20 in total

1.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Beware of ciprofloxacin in acute otitis media.

Authors:  C Marone; F Quadri
Journal:  BMJ       Date:  1992-10-10

Review 3.  Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

Authors:  H Lode
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

4.  In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 7.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.

Authors:  M C Sullivan; B W Cooper; C H Nightingale; R Quintiliani; M T Lawlor
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

Authors:  T J Louie
Journal:  CMAJ       Date:  1994-03-01       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.